NASDAQ:YARW

Yarrow Bioscience Q4 2025 Earnings Results & Report

Yarrow Bioscience logo
$14.35 +0.00 (+0.03%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Yarrow Bioscience reported Q4 2025 earnings on February 27, 2026. The company reported EPS of -$7.45, while revenue was $130 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Conference Call
7:00 AM ET

Yarrow Bioscience EPS Results

Actual EPS
-$7.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Yarrow Bioscience Revenue Results

Actual Revenue
$130 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Yarrow Bioscience Q4 2025 Earnings FAQ

Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$7.45 per share for Q4 2025. The report was announced on Friday, February 27, 2026.

Yarrow Bioscience reported revenue of $130 thousand for Q4 2025.

Yarrow Bioscience Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Yarrow Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View Yarrow Bioscience Profile